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Cisplatin, one of the most effective and potent anticancer drugs, is used in the treatment of a wide variety of both pediatric and
adult malignancies. However, the chemotherapeutic use of cisplatin is limited by its serious side effects, such as nephrotoxicity and
ototoxicity. Ototoxicity produced by cisplatin is usually persistent, depending on the age of the patient, the cumulative number
of doses, the number of chemotherapy cycles, the history of noise exposure, and deteriorating renal function. The mechanism
of the ototoxicity caused by cisplatin is based on the generation of reactive oxygen species, which interfere with the antioxidant
protection of the organ of Corti. Thus, protecting the cochlea with antioxidants ameliorates ototoxicity from cisplatin. In this
context, melatonin appears as a therapeutic option for preventing the ototoxic effects of cisplatin, since the research in the last
decade has proven its ability to be both a direct free radical scavenger and indirect antioxidant. In this sense, some of the evidence
suggesting that melatonin is efficient for combating cisplatin-induced ototoxicity is summarized and discussed in this paper.
1. Introduction
Cisplatin is an antineoplastic drug widely used in the treat-
ment of various types of cancer, mainly solid tumors like tes-
ticular, ovarian, lung, head, and neck cancers. Nevertheless,
its collateral effects, such as nephrotoxicity, neurotoxicity, and
ototoxicity, limit its use. Some of these side effects, such as
ototoxicity, are dose dependent and this fact prohibits the
use of higher doses, which could maximize its antineoplastic
activity.
While the nephrotoxicity can be diminished or controlled
with hydration therapy and diuretics, ototoxicity still remains
without an effective treatment. In the last year, many drugs
have been studied in an attempt to reduce the cochlear
damage induced by cisplatin.
Cisplatin-induced ototoxicity is usually manifested by
bilateral, progressive, and usually irreversible sensorineural
hearing loss, initially occurring in the higher frequencies
since cisplatin primarily damages outer hair cells from the
basal turn of cochlea and the spiral ganglion neurons [1].
Although ototoxicity caused by cisplatin may occur
within hours to days after drug administration, delayed oto-
toxicity from cisplatin may occur in children [1]. Approxi-
mately 23–54% of adults and 45% of pediatric patients with
head and neck cancer treated with cisplatin develop ototox-
icity [2].
There are several risk factors to cisplatin-induced hearing
loss, among which are cumulative doses, age, exposure to
other ototoxic drugs, cranial irradiation, depleted nutritional
state, renal insufficiency, noise exposure, and preexisting
hearing loss [3–5].
There have also been several publications suggesting a
relationship between genes and susceptibility to cisplatin oto-
toxicity. Certain gene polymorphisms appear to play a role
in increasing or decreasing the likelihood of ototoxicity
in patients treated with cisplatin chemotherapy. Cisplatin-
induced hearing loss has also been studied in patients with
mitochondrial mutations [6].
Many cisplatin protective agents have been evaluated in
experimental and clinical studies in an effort to amelio-
rate cisplatin-induced ototoxicity. Some drugs may protect
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against ototoxicity; however they may also reduce the anti-
neoplastic activity of cisplatin, which would have disastrous
effects on the patients’ prognosis.
In this scenario, melatonin appears as a potentially useful
substance in preserving audibility. The purpose of this paper
was to review articles concerning the potential effect of mela-
tonin as a protective agent against cisplatin-induced oto-
toxicity. Some of the evidence suggesting that melatonin is
efficient in combating cisplatin-induced ototoxicity will be
summarized and discussed in this paper.
2. Cisplatin-Induced Ototoxicity Mechanism
Various drugs and toxins present in the circulation or the
middle ear may reach the inner ear and cause a loss of audi-
tory sensitivity. Cisplatin and some antibiotic substances
cause the most important clinical form of ototoxicity.
Cell death in tumor cells is primarily through apoptosis,
although tumor cells in vitro may undergo necrosis when
exposed to high concentrations of cisplatin [4]. The effect
of cisplatin as an antineoplastic drug is due to its cytotoxic
action. It is characterized as being analogous to that of the
alkylating agents. However, as opposed to classic alkylating
agents, cisplatin binds to the DNA to form intrastrand
crosslinks and adducts that cause changes in the conforma-
tion of the DNA and affect DNA replication [7].
Other mechanisms of cisplatin cytotoxicity include mito-
chondrial damage, decreased ATPase activity, and altered
cellular transport mechanisms. While considered cell cycle
nonspecific, cytotoxicity is increased with exposure during
the S-phase. Cisplatin causes cell cycle arrest in the G2-phase
and then induces programmed cell death or apoptosis [8].
Cisplatin activates nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase, an enzyme that produces super-
oxide radicals, leading to a dramatic increase in superoxide
production in cochlear cell lines. Superoxide can lead to the
formation of hydrogen peroxide. The latter can be catalyzed
by iron to form the very reactive hydroxyl free radical [4].
Ototoxicity appears to be associated with high peak
cisplatin levels and is attributed to cisplatin’s ability to
generate reactive oxygen species (ROS) [4]. ROS can then
deplete cochlear tissues of antioxidant protective molecules,
for example, glutathione and antioxidant enzymes. This
may allow lipid peroxidation, as shown by increased con-
centrations of malondialdehyde, toxic lipid peroxides, and
aldehydes. These can increase calcium influx and apoptosis
in cells of the cochlea [5].
Cisplatin causes changes in the cochlear histology struc-
ture, such as the loss of the normal cytoarchitecture of the
organ of Corti and reduction of neurons in the spiral ganglion
due to cell alterations [9].
3. Melatonin
Melatonin is a remarkably diverse molecule that has been
identified in species throughout the animal kingdom and,
in the last decade, it has also been found in plants [10].
Melatonin is synthesized and released into the circulation
and particularly into cerebrospinal fluid by the pineal gland.
Immune system cells, the brain, the airway epithelium, bone
marrow, ovaries, the skin, and probably other tissues also
produce it.The production of melatonin increases during the
period of darkness and ismaintained atminimal levels during
the period of light, giving rise to a circadian rhythm that is
imposed by the light/dark cycle [11].
Besides its properties as a circadian rhythm transducer,
several other actions for this interesting molecule have been
uncovered in the last three decades. Melatonin participates
in many important physiological functions, including the
control of seasonal reproduction as well as influences on
the immune system and numerous other biological activities
[12, 13].
Additionally, melatonin seems to decrease toxicity and
increase the efficacy of cancer chemotherapy [14]. There is
evidence that melatonin anticancer activity is due to either
cytostatic mechanisms or cytotoxic action which triggers
the apoptotic machinery [15]. Furthermore, chemotherapy-
induced cytotoxicity may be due, at least in part, to enhanced
free radical generation and melatonin is one of the most
potent antioxidant agents [16]. Its direct free radical scav-
enging activity and its regulation of gene transcription for
antioxidative enzymes are of special interest in this review.
From a chemical point of view, free radicals are species
containing one or more unpaired electrons. This charac-
teristic makes them a highly reactive species that triggers
chain reaction mechanisms, which may involve molecules of
high biological importance, such as DNA and proteins. Most
radicals that occur in vivo are, or arise from, reactive oxygen
species (ROS) or reactive nitrogen species (RNS). In healthy
organisms, there is a delicate balance between the production
and the removal of free radicals. Under such conditions,
free radicals have a beneficial effect since they are necessary
for the maturation process of cellular structures, mitogenic
responses, defense system, cellular signaling systems, and
insulin receptor kinase activity and in the apoptosis of
defective cells [16].
However, at high concentrations, free radicals can be
extremely harmful to living organisms. The role of free radi-
cals in the development of a large variety of chronic and
degenerative diseases, such as in Parkinson’s disease, Alz-
heimer’s disease, multiple sclerosis, several cardiovascular
diseases, rheumatoid arthritis, fetal growth restriction, pree-
clampsia, and cancer, is well documented [16].
Melatonin and its metabolites efficiently protect against
oxidative stress through a variety of mechanisms [16, 17]. It
has the ability to scavenge a wide variety of ROS and RNS,
and it has been hypothesized that its primary function in
living organisms is to protect them from oxidative stress
[18]. Melatonin has most of the desirable characteristics of
good free radical scavengers: it is widely distributed in the
body and present in adequate concentrations; it is a broad
spectrum antioxidant; it is easily transported across cellular
membranes; it crosses all morphophysiological barriers; it
can be regenerated, after radical quenching, and its metabo-
lites still present antioxidant activity. Finally, it has minimal
toxicity [16, 19].
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Melatonin detoxifies a variety of free radicals and reactive
oxygen intermediates and stimulates several antioxidative
enzymes. Antioxidant enzymes activities and also their gene
expression exhibit endogenous rhythms under normal light/
dark conditions. These changes with time suggested that
these cycles might be dependent on the circadian melatonin
rhythm [20].
Antioxidants, such as melatonin, have attracted a great
deal of attention as potential agents for forestalling age-
related free radical-based diseases. It is already a well-known
possibility that melatonin supplementation could prevent or
delay the functional deterioration of the immune system that
accompanies aging. Indeed, dietary supplementation ofmela-
tonin ameliorates the debilitated immune responses asso-
ciated with senescence [21, 22].
Based on a substantial amount of data documenting
melatonin’s ability to reduce neural damage in models of Alz-
heimer’s disease, several groups have administeredmelatonin
to individuals diagnosed with this neurodegenerative condi-
tion in an attempt to ameliorate the disease’s symptoms [23–
26].
Melatonin has also been tested as an agent to reduce
oxidative stress in adult humans subjected to cardiopul-
monary bypass surgery to reduce the severity and degree of
tissue damage following ischemia/reperfusion in the brain
and other organs and to prevent degenerative changes in
Parkinson’s disease [27–29].
Melatonin has proven to be useful as a treatment for septic
shock in premature newborns as well. This beneficial action
of melatonin is attributed to the antioxidant properties since
multiple organ failure and death in sepsis are believed to be
due, at least in part, to excessive free radical generation. Its
use in adults also seems justified [30].
Because of its actions as a direct free radical scavenger
and indirect antioxidant, melatonin reduces the toxicity and
increases the efficacy of a large number of drugs whose side
effects are well documented. Reiter et al., in 2002, sum-
marize the beneficial effects of melatonin when combined
with the following drugs: doxorubicin, cisplatin, epirubicin,
cytarabine, bleomycin, gentamicin, ciclosporin, indometacin,
acetylsalicylic acid, ranitidine, omeprazole, isoniazid, iron
and erythropoietin, phenobarbital, carbamazepine, haloperi-
dol, caposide-50, morphine, cyclophosphamide, and L-
cysteine [12].
A variety of otoprotective compounds have been suc-
cessfully used in experimental animals. The ideal protective
agent, if given systemically, should have three characteristics:
it should be nontoxic, it should achieve sufficiently high con-
centrations in the inner ear, and it must not interfere with
the antitumor effect of cisplatin. Considering the low toxicity
of melatonin and its ability to reduce the side effects and
increase the efficacy of the drugs, its use as a combination
therapywith cisplatin seems important andworthy of pursuit.
3.1. Oncostatic Properties of Melatonin. The therapeutic
potential of melatonin goes beyond the treatment of jet lag
or sleep disorders. It has been shown that it has antitumoral
properties in many experimental conditions. A large number
of studies have demonstrated that melatonin has important
oncostatic properties since it inhibits cell proliferation in
several cancer cell lines and additionally reduces the toxicity
of antineoplastic drugs.
Melatonin has been described to reduce not only the
incidence but also the cancer cell growth. Melatonin inhibi-
tion of cell growth, invasiveness, and metastatic properties
in tumoral cell cultures, mainly endocrine tumours, has
been reported. Additionally, synergy between melatonin and
several chemotherapeutic drugs in the induction of apoptosis
has also been published [31, 32]. The exact mechanism by
which melatonin exerts its antitumoral actions is not fully
understood.
Melatonin acts as a regulator for neoplastic cell growth,
particularly on tumors corresponding to the mammary
gland. Experimental manipulations activating the pineal
gland, or the administration of melatonin, reduce the inci-
dence and growth rate of chemically induced mammary
tumors in rodents, while pinealectomy or situations that
implicate a reduction of melatonin production usually stim-
ulate mammary carcinogenesis [33].
The antiproliferative actions of melatonin on human
breast cancer cells in vitro have been confirmed by numerous
laboratories and have also been seen in other tumor types,
including prostate cancer, ovarian cancer, endometrial can-
cer, liver cancer, and osteosarcomas [34]. Physiologic con-
centrations of melatonin, corresponding to peak daytime and
peak night-time serum values in humans, can significantly
suppress the proliferation of both the estrogen receptor alpha-
positive and the negative human breast cancer cells in vitro
[35, 36].
Concomitant administration of melatonin significantly
reduces the frequency of thrombocytopenia, neurotoxicity,
cardiotoxicity, stomatitis, and asthenia in chemotherapy with
cisplatin for lung cancer [14, 37]. The possibility of improve-
ment in the efficacy of chemotherapy is already known
in terms of both survival and quality of life through the
concomitant administration of melatonin in a considerable
number of patients with metastatic non-small-cell lung can-
cer and for a long follow-up period [38].
Melatonin has cytotoxic activity against several hema-
tological cancer cell lines. Hematological malignancies fre-
quently show defective apoptosis and downregulation of
death receptors. Melatonin’s cytotoxic effects are attributed to
the activation of the extrinsic pathway of apoptosis. Melato-
nin also induces cell death in hematological cancer cells
obtained from the peripheral blood and bone marrow of
patients with acute lymphoid leukemia [39, 40].
Melatonin, besides its cell growth inhibition and cell
cycle perturbation, triggers apoptosis in lymphoblastic cells
via a specific effect on mitochondrial membrane potential,
leading to cytochrome c release and caspase-3 activation and
playing an important role as a potential therapeutic drug in
lymphoproliferative diseases [41].
Additionally, melatonin reduces the growth of the human
myeloid leukemia cells HL-60, inhibiting progression from
G1 to the S phase of the cell cycle and increasing apop-
totic cell death. Furthermore, melatonin treatment elevates
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cytochrome c release from the mitochondria and augments
caspase-3 and caspase-9 activities [42].
Neuroblastoma, a pediatric cancer, which is most com-
mon before the age of 10, has its total number of cells
reduced with increasing concentrations of melatonin [43].
Glioblastoma, the most common primary brain tumor, is a
highly aggressive malignancy considered to be one of the
most lethal cancers. The combination of chemotherapy and
melatonin appears as a new approach in glioblastoma treat-
ment [44–46].
Melatonin has been shown to induce cytotoxicity in the
Ewing sarcoma cell line. Ewing sarcoma is the second most
frequent type of bone cancer and affects mainly adolescents,
who have a 50% survival rate 5 years after diagnosis. Current
treatments include a combination of surgery, radiotherapy,
and chemotherapy, which present potential serious side
effects. Melatonin creates a synergy in the antitumor effect
when combined with chemotherapeutic drugs. This syner-
gism is due to the potentiation of cell death and there is a
significant increase in the activation of both intrinsic and
extrinsic apoptotic pathways when melatonin is combined
with the treatment [47, 48].
3.2. Action against the Side Effects of Cisplatin. Reversible and
irreversible side effects of melatonin including nephrotoxic-
ity, bone marrow toxicity, gastrointestinal toxicity, neurotox-
icity, and ototoxicity may limit its utility and therapeutic pro-
file. Melatonin may play an important role in the prevention
of these side effects.
Several antioxidant agents have been reported to either
ameliorate or prevent the nephrotoxicity of cisplatin includ-
ing melatonin, selenium, vitamins E and C, N-acetylcysteine,
and many others [49]. Melatonin protects against oxidative
damage associated with cisplatin in rat kidneys. The mecha-
nism of cisplatin-induced nephrotoxicity has been postulated
as follows: when cisplatin accumulates in the kidney, ROS
are generated and cells undergo oxidant stress, resulting in
cytotoxicity and leading to cell death [17].
Depletion of renal glutathione and glutathione peroxi-
dase, as well as an increase in lipid peroxidation, has been
observed as a result of cisplatin administration. The mela-
tonin cotreatment restores the activity of the antioxidant
enzyme glutathione peroxidase [49–51].
Serum creatinine and urea nitrogen significantly increase
following cisplatin administration in rats, and these values
decrease significantly with melatonin cotreatment [52]. His-
tological analysis shows that cisplatin causes damage in the
proximal tubular cells in the kidneys of cisplatin-treated rats
and these changes are also reversed bymelatonin cotreatment
[52]. It has been suggested that melatonin administration,
even after cisplatin injection, still has protective effects, unlike
other antioxidants [53].
Cisplatin chemotherapy has been reported to cause a
variety of vascular side effects. There are reports of venous
thromboembolic events, cerebrovascular and cardiovascular
arterial occlusion in patients treated with cisplatin. Phenyle-
phrine and KCl produce concentration-dependent contrac-
tions of the rat aorta. Treatment with cisplatin increased the
sensitivity to phenylephrine and KCl. Melatonin cotreatment
decreased the sensitivity to both contractile agents [54].
Another benefit of melatonin cotherapy that has already
been demonstrated is protection against testicular damage.
Oxidative stress caused by free radicals plays an important
role in the development of cisplatin-induced testicular dam-
age, and melatonin has a potent protective effect against
the testicular toxicity of this agent [55]. Cisplatin treatment
causes a decrease in the epididymal sperm concentration and
in the sperm motility. Treatment with melatonin provided
moderate normalization of sperm concentration and full
recovery of sperm motility [56]. Thus melatonin may play a
role as a potential therapeutic agent for impairment of tes-
ticular function that is induced by cytotoxic chemotherapies
[55].
3.3.Melatonin Effect againstOtherDrugsOtotoxicity. Ototox-
icity caused by gentamicin and tobramycin is ameliorated by
melatonin and the pineal hormone does not interfere with
their antibiotic capacity [57, 58]. This discovery supports the
hypothesis that melatonin has a role in ototoxicity prevention
related to the protective effect in the outer hair cells of the
organ of Corti.
Gentamicin induces loss of utricular hair cells in rats, and
this effect is significantly attenuated by coadministration of
melatonin. Melatonin reduced reactive oxygen species pro-
duction and caspase-3 activation in the gentamicin treated
utricular hair cells [59]. Guinea pigs receiving melatonin
cotherapy have hearing loss significantly attenuated and their
cochleae show lower rates of outer hair cell loss compared
with animals treated exclusively with gentamicin [19].
It has been shown that melatonin administrated locally
through catheters placed in the round window membrane
niches of cochlea or through pieces of gelfoam placed in the
round window membrane niches has otoprotective proper-
ties that could be beneficial in the treatment of gentamicin-
induced hearing loss. The development of local long-term
delivery techniques to the cochlea could be an alternative in
terms of reducing the levels of drugs required for effective
treatment, decreasing or eliminating side effects, and avoid-
ing alteration of drugs by liver metabolism, thereby assuring
that the desired concentration of a drug is achieved only in
the target area, that is, the perilymphwithin the scala tympani
[60].
Low-dose melatonin administration also protects the
inner ear from amikacin-induced ototoxicity. However, high
dose melatonin facilitates its ototoxicity, possibly via the
vasodilator effect, leading to an increased accumulation of
amikacin in the inner ear [61].
3.4. Antioxidants Acting against Cisplatin-InducedOtotoxicity.
It has been demonstrated that plasma concentrations of
various antioxidants significantly decreased during cisplatin-
based chemotherapy in cancer patients. It is well known
that, in hearing loss associated with cisplatin, free oxygen
radicals are produced in the outer hair cells, spiral ganglion
stria vascularis, and in the cochlea. Several antioxidant
substances have revealed protective effects against cisplatin
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ototoxicity in animalmodels and in human studies.The exog-
enous application of antioxidant molecules has become the
primary focus in the treatment strategies of cisplatin-induced
ototoxicity.
Vitamin C, vitamin E, and L-carnitine are important nat-
ural antioxidants, which are synergistically able to interfere
with the harmful reactions initiated by free radicals. They
were found to make a significant contribution to decreasing
or preventing cisplatin-induced ototoxicity in rats [62, 63].
Resveratrol, a natural polyphenolic nonflavonoid antiox-
idant, has been shown to have significant anti-inflammatory,
antioxidant, and immunomodulatory properties. Its antioxi-
dant propertiesmainly depend on the upregulation of endog-
enous cellular antioxidant systems, but the compound also
shows direct ROS-scavenging properties. Cisplatin-related
ototoxicity has been greatly prevented by resveratrol use [64,
65].
Ginkgo biloba extract (EGB761) shows potential otopro-
tector effect because of its antioxidant properties [66]. This
protective action was also revealed in several studies [67–
70]. The association of ginkgo biloba extract with cilostazol
may have a synergistic effect by strongly protecting hearing
and vestibular dysfunction induced by cisplatin by inhibiting
reactive oxygen species production, mitochondrial pathways,
and the p-extracellular regulated kinase pathway without
interfering with cisplatin pharmacokinetics [71].
Edaravone, another free radical scavenger, can interact
with both peroxyl and hydroxyl radicals to form oxidized
compounds and it attenuates cisplatin-induced hair cell dam-
age and ultrastructural changes in zebrafish by reducing free
radicals [72]. Systemic administration of thiamine pyrophos-
phate yielded statistically significant protection fromcisplatin
toxicity in the cochlea of guinea pigs. Itmay also be a potential
drug candidate for humans [73].
D-methionine, a sulfur-containing compound, either
administered systemically or through the round window
membrane, has been shown to protect from cisplatin-induced
ototoxicity. Further, D-methionine does not interfere with
cisplatin’s antitumor action [74]. D-methionine has been
studied extensively in the prevention of cisplatin-induced
hearing loss [75, 76].
N-acetylcysteine, a precursor to glutathione, is an antiox-
idant that limits the extent of the oxidative stress damage to
the cell and is able to improve the oxidant/antioxidant cellular
balance. N-acetylcysteine may protect the inner ear from the
ototoxic effects of cisplatin both by acting as a free radical
scavenger and by inducing the production of endogenous
antioxidants [77].
Rosmarinic acid has been reported to have antioxidative,
anti-inflammatory, and antidepressive activities. It inhibited
cisplatin-induced apoptosis via inhibition of ROS generation
and other mechanisms. In this respect, it may be attributed
to a decrease in the ototoxic side effect of cisplatin in humans
[78].
It is known that, at times, high doses of these drugs
are required to achieve the desired effects against cis-
platin ototoxicity, and their systemic application may result
in decreased efficacy of cisplatin’s tumoricidal properties,
among other collateral effects. Therefore, intratympanic
administration of drugs is a method of locally treating inner
ear disorders by allowing diffusion across the round window
into the inner ear.Thismethod allows higher concentration of
drugs within the inner ear compared with oral or parenteral
routes.
Vitamin C, a powerful antioxidant, reduces the cytotoxic
effects of antineoplastic drugs. However, high doses of vita-
min C are required to achieve the desired effects, which is
substantially higher than the maximum dose a person can
take daily. Intratympanic application of vitamin C protects
against cisplatin-induced ototoxicity. In addition, intratym-
panic application of vitamin C does not produce a toxic effect
on the cochlea, suggesting that the intratympanic method
might be a safe drug delivery route for vitamin C [79].
Vitamin E, a slow-acting free radical scavenger, has a sig-
nificant protective effect on hearing functions which are
damaged by cisplatin in rats. Vitamin E may minimize inner
ear damage induced by cisplatin. Intratympanic application is
safer and easier and no significant adverse effects in hearing
are seen [80]. Intratympanic infusions of N-acetylcysteine
may offer significant protection against cisplatin-induced
inner ear toxicity [77].
Intratympanic administration of dexamethasone also
reduces ototoxicity from systemic cisplatin. It reduces the for-
mation of free radicals and protects hearing in animalmodels.
Intratympanic dexamethasone administration is a safe, easy,
and efficient way to protect from cisplatin ototoxicity, espe-
cially when administered one hour before cisplatin treatment
[80–83].
Despite the fact that several drugs had been used in
an attempt to prevent cisplatin-ototoxicity, melatonin seems
to have a potential advantage, because it is known to be
nontoxic, it achieves sufficiently high concentrations in the
inner ear, and it apparently does not impair the antitumor
effect of cisplatin.
3.5. Potential Use of Melatonin. There is a great deal of the-
oretical support for melatonin use against cisplatin-induced
ototoxicity. Moreover, several studies have already found that
melatonin could be effective in reducing the nephrotoxicity
of cisplatin and the ototoxicity of some antibiotics, such as
gentamicin and amikacin.
Lopez-Gonzalez et al., in 2000, studied the ototoxic
effect of cisplatin in rats. Besides cisplantin, melatonin and
a mixture of antioxidants consisting of alpha-tocopherol suc-
cinate, ascorbic acid, glutathione and N-acetylcysteine were
administered. Since the mechanism of the ototoxicity caused
by cisplatin is based on the generation of reactive oxygen
species, which interfere with the antioxidant protection of the
organ of Corti, they hypothesized that the protection of the
cochlea with antioxidants ameliorates the ototoxicity from
cisplatin. The distortion product otoacoustic emissions were
determined for a prolonged period of time for each animal.
The ototoxicity produced by cisplatin was maximal from day
7 to day 10 after treatment, returning to normal values in a
month. When melatonin and the antioxidant mixture were
present, the recovery time was between 10 and 15 days after
treatment, independent of themeans of administration of the
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pineal product. They conclude that the ototoxicity caused by
cisplatin is ameliorated by melatonin and other antioxidants
[11].
4. Conclusion
Thus, melatonin appears to have a potential effect against cis-
platin-induced ototoxicity.There is ample justification for the
assumption that melatonin may be capable of overcoming
hearing loss due to cisplatin treatment. Nevertheless, further
studies are necessary to clarify the specific role of melatonin
as a protective substance in the auditory system and certify
that melatonin does not impair the antineoplastic effect of
cisplatin.
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